News

Applied Clinical Trials Online47m
Gilead’s Yeztugo Demonstrates Strong HIV Prevention Results in Underserved Populations
Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...